All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
Introducing
Now you can personalise
your GvHD Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
During the EHA2021 Virtual Congress, the GvHD Hub spoke with Eduardo Rodriguez Arboli, University of Seville, Seville, ES. We asked, Are you planning a phase II study of glasdegib in refractory sclerotic chronic GvHD?
Are you planning a phase II study of glasdegib in refractory sclerotic chronic GvHD?
In this video, Arboli reports on the results of a phase I study evaluating the safety and efficacy of glasdegib in patients with sclerotic chronic GvHD. He discusses tolerability, dosing, calcium channel blockers for muscle cramps, and the ongoing phase II study.
Subscribe to get the best content related to GvHD delivered to your inbox